Karuna Therapeutics was founded in July 2015 to develop treatments based on its unique understanding of brain chemistry and biology. The company has raised over $60 million in venture capital to date, and has built a robust product pipeline, highlighted by its lead compound, KarXT, a novel, orally-active modulator of multiple muscarinic receptors for the treatment of schizophrenia and other CNS disorders.
